Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Cad Saude Publica. 2020;36(7):e00136419. doi: 10.1590/0102-311x00136419. Epub 2020 Jul 17.
Cutaneous leishmaniasis (CL) is a disease associated with low-income populations. Thus, in assessing the burden of this disease, it is important to include its economic impact on individuals. We aimed to evaluate CL economic impact on patients treated at a referral service in the State of Minas Gerais, Brazil. This is a cross-sectional study based on the analysis of interviews and medical records from which we assembled direct medical and non-medical costs related to CL, from a societal perspective. One hundred patients were included; 50% had a monthly per capita income of up to USD 259.60 and spent on average USD 187.32 with the disease, representing an average monthly impact of 22.5% (USD 133.80). The disease imposed direct medical costs, such as: private medical appointments, medications, medical exams, dressing material, and co-participation in health insurances. Direct non-medical costs were mainly related to patients' transportation to health centers (USD 4,911.00), but also included medically-necessary care, food, and domestic and business outsourcing services. Although the Brazilian public health system guarantees access to health care, CL still represents a substantial economic impact for patients. The main action to reduce the expenses with this disease is decentralizing services for CL diagnosis and therapeutic approach, as well as increasing their efficiency.
皮肤利什曼病(CL)是一种与低收入人群相关的疾病。因此,在评估这种疾病的负担时,重要的是要包括其对个人的经济影响。我们旨在评估巴西米纳斯吉拉斯州一家转诊服务机构治疗的 CL 对患者的经济影响。这是一项基于访谈和病历分析的横断面研究,我们从社会角度综合了与 CL 直接相关的医疗和非医疗费用。共纳入 100 例患者,其中 50%的患者月人均收入在 259.60 美元以下,平均每人因 CL 花费 187.32 美元,占月人均收入的 22.5%(133.80 美元)。该疾病产生了直接医疗费用,例如:私人医疗预约、药物、医学检查、敷料和医疗保险共付额。直接非医疗费用主要与患者前往医疗中心的交通费用(4911.00 美元)有关,但也包括医疗必需的护理、食品以及家庭和商业外包服务。尽管巴西公共卫生系统保障了医疗保健的可及性,但 CL 仍然对患者造成了重大的经济影响。减少此类疾病费用的主要措施是为 CL 的诊断和治疗方法提供服务的分散,并提高其效率。
Biomed Res Int. 2018-10-11
Front Sociol. 2021-6-29
PLoS Negl Trop Dis. 2025-4-15
Res Rep Trop Med. 2021-6-23
Rev Inst Med Trop Sao Paulo. 2021